Is Immunocore Holdings Stock a Good Investment?
Immunocore Holdings Investment Advice | IMCR |
- Examine Immunocore Holdings' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Immunocore Holdings' leadership team and their track record. Good management can help Immunocore Holdings navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceutical Products space and any emerging trends that could impact Immunocore Holdings' business and its evolving consumer preferences.
- Compare Immunocore Holdings' performance and market position to its competitors. Analyze how Immunocore Holdings is positioned in terms of product offerings, innovation, and market share.
- Check if Immunocore Holdings pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Immunocore Holdings' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Immunocore Holdings stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Immunocore Holdings is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Not Available | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Immunocore Holdings Stock
Researching Immunocore Holdings' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 95.0% of the company shares are owned by institutional investors. The book value of Immunocore Holdings was currently reported as 7.55. The company recorded a loss per share of 0.95. Immunocore Holdings had not issued any dividends in recent years.
To determine if Immunocore Holdings is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunocore Holdings' research are outlined below:
| Immunocore Holdings generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 249.43 M. Net Loss for the year was (43.37 M) with profit before overhead, payroll, taxes, and interest of 54.11 M. | |
| Over 95.0% of the company shares are owned by institutional investors |
Immunocore Holdings uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunocore Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunocore Holdings' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Immunocore Holdings' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.64 B.Immunocore Holdings' profitablity analysis
The company has Profit Margin (PM) of (0.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.11) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.11.Determining Immunocore Holdings' profitability involves analyzing its financial statements and using various financial metrics to determine if Immunocore Holdings is a good buy. For example, gross profit margin measures Immunocore Holdings' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunocore Holdings' profitability and make more informed investment decisions.
Basic technical analysis of Immunocore Stock
As of the 29th of November, Immunocore Holdings retains the Standard Deviation of 2.42, market risk adjusted performance of (1.14), and Risk Adjusted Performance of (0.03). Immunocore Holdings technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Immunocore Holdings variance and potential upside to decide if Immunocore Holdings is priced fairly, providing market reflects its last-minute price of 32.83 per share. Given that Immunocore Holdings has information ratio of (0.1), we strongly advise you to confirm Immunocore Holdings's regular market performance to make sure the company can sustain itself at a future point.Immunocore Holdings' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunocore Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunocore Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunocore Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Immunocore Holdings' Outstanding Corporate Bonds
Immunocore Holdings issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Immunocore Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Immunocore bonds can be classified according to their maturity, which is the date when Immunocore Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Immunocore Holdings' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Immunocore Holdings' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (1.14) | |||
| Mean Deviation | 1.92 | |||
| Coefficient Of Variation | (2,207) | |||
| Standard Deviation | 2.42 | |||
| Variance | 5.86 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (1.15) | |||
| Maximum Drawdown | 10.38 | |||
| Value At Risk | (3.87) | |||
| Potential Upside | 2.97 | |||
| Skewness | (0.32) | |||
| Kurtosis | 0.3379 |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (1.14) | |||
| Mean Deviation | 1.92 | |||
| Coefficient Of Variation | (2,207) | |||
| Standard Deviation | 2.42 | |||
| Variance | 5.86 | |||
| Information Ratio | (0.1) | |||
| Jensen Alpha | (0.13) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (1.15) | |||
| Maximum Drawdown | 10.38 | |||
| Value At Risk | (3.87) | |||
| Potential Upside | 2.97 | |||
| Skewness | (0.32) | |||
| Kurtosis | 0.3379 |
Consider Immunocore Holdings' intraday indicators
Immunocore Holdings intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Immunocore Holdings stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Immunocore Holdings time-series forecasting models is one of many Immunocore Holdings' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunocore Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Immunocore Stock media impact
Far too much social signal, news, headlines, and media speculation about Immunocore Holdings that are available to investors today. That information is available publicly through Immunocore media outlets and privately through word of mouth or via Immunocore internal channels. However, regardless of the origin, that massive amount of Immunocore data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunocore Holdings news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunocore Holdings relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunocore Holdings' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunocore Holdings alpha.
Immunocore Holdings Corporate Management
| Sbastien Desprez | Head Communications | Profile | |
| Debra Nielsen | Chief Staff | Profile | |
| JD Esq | Chief Officer | Profile | |
| Annelise Vuidepot | CTO Research | Profile | |
| Brian MBA | CFO Strategy | Profile | |
| Amy JudgePrein | Chief Officer | Profile |
Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.